在美国社区环境中,对HER2-阴性早期乳腺癌患者的基因测试和治疗模式
Kathryn E Mishkin1, Yezhou Sun2, Ke Meng2
1Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, United States.
Frontiers in oncology
|March 16, 2026
概括
在美国,早期乳腺癌 (eBC) 的BRCAm检测率低于最佳水平. 在手术前进行基因检测至关重要,以指导HER2-阴性eBC患者的治疗决策.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 现实世界的证据.
背景情况:
- 辅助性olaparib被批准用于高风险的HER2-阴性早期乳腺癌 (eBC) 具有BRCA突变 (gBRCAm).
- 需要对美国HER2-阴性eBC中BRCAm测试模式,流行率和治疗选择的真实数据.
研究的目的:
- 描述BRCAm测试模式和在美国患有HER2-阴性eBC的患者的患病率.
- 在这个人群中分析基于BRCAm状态的治疗选择.
主要方法:
- 使用美国社区医疗保健系统数据的回顾性队列研究 (2022年1月至2024年1月).
- 包括临床阶段I-III HER2-负BC的成年人;排除了未知HR状态的患者,在临床试验中,或在现场的叶状癌.
- 描述了BRCAm测试特征和BRCAm状态的后续治疗.
主要成果:
- 在3741名患者中,BRCAm测试率分别为51% (2022) 和56% (2023).
- 在5%的测试患者中发现了BRCA突变的eBC (3%HR+/HER2阴性,13%TNBC).
- 在18名患者中使用了辅助olaparib;73%的BRCA突变HR+eBC和45%的BRCA突变TNBC接受了辅助治疗.
结论:
- 美国的BRCAm检测率对于HER2阴性eBC,特别是对HR+/HER2阴性亚型来说,低于最佳水平.
- 建议在手术前进行基因检测,以告知对HER2-阴性eBC的治疗决策.
- 提高检测率和时间对于最佳的患者管理至关重要.
关键词:
这就是BRCA BRCA.辅助疗法是一种辅助疗法.生物标志物测试是对生物标志物进行测试的.乳腺癌 乳腺癌 乳腺癌内分泌疗法是一种内分泌疗法.现实世界的研究研究.复发性 复发性 复发性有针对性的治疗.更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.7K
09:24Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
9.7K
相关概念视频
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Survival Analysis
812
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
812
Treatment Resistent Cancers
1.5K
1.5K
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
